Eli Lilly and Company $LLY Shares Purchased by Trust Point Inc.

Key Points

• Trust Point Inc. increased its stake in Eli Lilly by 21.8% in Q2, owning a total of 3,476 shares valued at approximately $2.71 million.
• CEO David A. Ricks purchased 1,632 shares at an average price of $644.77 per share, increasing his ownership to over $352.43 million.
• Eli Lilly's recent earnings report showed $6.31 EPS, significantly exceeding expectations, with a 37.6% year-over-year revenue increase to $15.56 billion.

Trust Point Inc. grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 21.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,476 shares of the company's stock after purchasing an additional 621 shares during the quarter. Trust Point Inc.'s holdings in Eli Lilly and Company were worth $2,710,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LLY. PNC Financial Services Group Inc. grew its stake in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the period. GAMMA Investing LLC boosted its position in Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares during the period. Nuveen LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth $4,613,912,000. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Finally, Cohen Investment Advisors LLC boosted its position in Eli Lilly and Company by 7,975.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock worth $647,225,000 after purchasing an additional 773,947 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Buying and Selling

In other news, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares of the company's stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 1.2%

Shares of LLY stock traded down $9.41 during trading hours on Friday, hitting $753.52. 7,319,147 shares of the company were exchanged, compared to its average volume of 3,181,974. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $939.86. The business's 50-day simple moving average is $738.37 and its two-hundred day simple moving average is $770.79. The stock has a market capitalization of $713.18 billion, a price-to-earnings ratio of 49.25, a P/E/G ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the company posted $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a research report on Sunday, August 17th. Guggenheim decreased their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Cantor Fitzgerald decreased their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. Finally, Berenberg Bank reissued a "hold" rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $939.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.